EntryPoint Capital LLC Purchases 38,663 Shares of Cerus Co. (NASDAQ:CERS)

EntryPoint Capital LLC boosted its position in Cerus Co. (NASDAQ:CERS) by 202.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 57,765 shares of the biotechnology company’s stock after acquiring an additional 38,663 shares during the period. EntryPoint Capital LLC’s holdings in Cerus were worth $109,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Neuberger Berman Group LLC bought a new position in Cerus in the fourth quarter worth approximately $26,000. Russell Investments Group Ltd. lifted its holdings in shares of Cerus by 451.1% in the first quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 12,179 shares in the last quarter. RPO LLC bought a new position in shares of Cerus in the fourth quarter valued at approximately $79,000. Virtu Financial LLC bought a new position in shares of Cerus in the fourth quarter valued at approximately $180,000. Finally, Aristides Capital LLC bought a new position in shares of Cerus in the fourth quarter valued at approximately $231,000. Institutional investors own 78.37% of the company’s stock.

Cerus Price Performance

Shares of CERS opened at $2.38 on Friday. The company has a quick ratio of 1.72, a current ratio of 2.41 and a debt-to-equity ratio of 1.29. The stock has a 50 day moving average of $1.91 and a 200 day moving average of $1.93. Cerus Co. has a 12 month low of $1.21 and a 12 month high of $3.08.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Cerus had a negative return on equity of 58.65% and a negative net margin of 19.27%. The firm had revenue of $38.37 million during the quarter, compared to analysts’ expectations of $36.40 million. As a group, analysts expect that Cerus Co. will post -0.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CERS shares. Craig Hallum started coverage on Cerus in a report on Friday, April 12th. They issued a “buy” rating and a $5.00 target price on the stock. Cantor Fitzgerald increased their price target on Cerus from $3.00 to $4.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.